2026-06-14T03:39:12Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/95062024-09-27T09:43:29Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605

00925njm 22002777a 4500 dc Rossello, Xavier author Piñero, Antonio author Fernandez-Jimenez, Rodrigo author Sanchez-Gonzalez, Javier author Pizarro, Gonzalo author Galan-Arriola, Carlos author Lobo-Gonzalez, Manuel author Vilchez, Jean Paul author Garcia-Prieto, Jaime author Garcia-Ruiz, Jose M author Garcia-Alvarez, Ana author Sanz-Rosa, David author Ibáñez, Borja author 2018-08 The administration of the selective β3 adrenergic receptor (β3AR) agonist BRL-37344 protects from myocardial ischemia/reperfusion injury (IRI), although the lack of clinical approval limits its translatability. We tested the cardioprotective effect of mirabegron, the first-in-class β3AR agonist approved for human use. A dose-response study was conducted in 6 pigs to select the highest intravenous dose of mirabegron without significant detrimental hemodynamic effect. Subsequently, closed chest anterior myocardial infarction (45 min ischemia followed by reperfusion) was performed in 26 pigs which randomly received either mirabegron (10 μg/kg) or placebo 5 min before reperfusion. Day-7 cardiac magnetic resonance (CMR) showed no differences in infarct size (35.0 ± 2.0% of left ventricle (LV) vs. 35.9 ± 2.4% in mirabegron and placebo respectively, p = 0.782) or LV ejection fraction (36.3 ± 1.1 vs. 34.6 ± 1.9%, p = 0.430). Consistent results were obtained on day-45 CMR. In conclusion, the intravenous administration of the clinically available selective β3AR agonist mirabegron does not reduce infarct size in a swine model of IRI. J Cardiovasc Transl Res. 2018; 11(4):310-318 10.1007/s12265-018-9819-8 1937-5395 1937-5387 Journal of cardiovascular translational research 30073540 http://hdl.handle.net/20.500.12105/9506 Acute myocardial infarction Cardioprotection Ischemia/reperfusion injury Mirabegron Translational models β3 adrenergic receptor Mirabegron, a Clinically Approved β3 Adrenergic Receptor Agonist, Does Not Reduce Infarct Size in a Swine Model of Reperfused Myocardial Infarction